Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study - Wikidata - wikimedia - TriplyDB

Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study

Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study

http://www.wikidata.org/entity/Q58235659

about

Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy KASL clinical practice guidelines: management of chronic hepatitis B Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL.Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.Virus and Host Testing to Manage Chronic Hepatitis B.Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults.Virological and serological tools to optimize the management of patients with chronic hepatitis B.Hepatitis B: treatment choice and monitoring for response and resistance.Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B.Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy.When can we stop nucleoside analogues in patients with chronic hepatitis B?New antivirals for the treatment of chronic hepatitis B.Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B.HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study.Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg.Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.Efficacy of interferon for chronic hepatitis B in patients with nucleoside and nucleotide combination therapy failure.Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability.Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy.Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update).Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation.HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study.

P2860

Q26740161-BF1EBE0B-C7F2-4026-85A5-B1B97A679BD9 Q26752475-AB13FD44-C631-4BD0-90FF-DFDAA1C646AA Q27020938-FDDF0759-CA8A-4EAF-95AA-5084D8ED7165 Q30391932-F144D3BE-BDC1-4FFC-8438-72F658E8DEAB Q33686951-48FDCB01-715C-4BE8-818F-DA5CB62C6388 Q35961444-7B677831-3D26-405C-9D28-B04AA84B4461 Q36195218-7A9C9EB3-4C5C-4695-AB2A-1FF1AF2C4407 Q36254363-5BA5A625-8827-4514-9318-8FD1BBF78CEC Q36958940-B94043C5-D76D-4907-AB1A-F7DADA22093F Q37343296-29819700-CD12-4324-A7DF-06767C9AC6FE Q37501060-CA851F92-6CD4-43BD-B5C6-BE2DCC507421 Q38238547-94150D6F-BB41-48D6-BC40-57911D228D1C Q38295840-ABC96FC2-235A-44BC-A40E-D3C9D4E2AE93 Q38295855-6371F0AF-64B9-4F5C-8082-3858BD1A0E24 Q38543596-B3A42475-3AB0-4698-80AB-B9008BB889D2 Q38648688-27130D24-1598-40BA-9CFB-C3647CFD3296 Q38685589-4A16B60F-87CF-4D22-90CE-402B5302DB57 Q38707903-624BF283-530F-44A9-A127-AEB7D36D6EB2 Q38811832-364166FC-0CC8-4D2C-85C3-6F9E159D6D78 Q38964920-C04E02FC-EA7B-400E-ABEC-23C435571BEB Q38999610-C56C7E4E-9E95-4C3F-9F05-82EEBF54033B Q39067306-DDEF652B-EEB9-4FD1-B100-CE74FB035F72 Q39315990-A5CC4E3A-6A23-4C01-A898-2E073715A8E3 Q40102464-86733DA5-A2BB-4618-A2AE-1C402375A516 Q40161294-3FED9153-D2F1-48F3-92A7-33A8E3F15961 Q40189344-DCA55740-EC54-4DAE-BDED-B6C2151D23FC Q40280136-028EC8FA-5EA6-42A0-B8D2-2B1B88F2ABA9 Q40361006-0BA000BB-6D5C-414C-8483-C462D967CA12 Q40423977-4A910D66-D3DB-4FBB-BB29-564909717410 Q40817492-EC07514F-A8A2-49BD-8148-7138176DD5ED Q40870495-8184879A-63F0-4303-841B-013CCD33F461 Q40957411-847D7911-779C-4FE2-A646-89D5C0C14759 Q41121379-86C6293C-CD74-4EC3-92C7-D68E6A1269FA Q41249783-599C6BB9-394A-4C3C-9E33-E88F17306CC8 Q41927231-0C17F782-D842-4972-89EB-62F95FF4EF5A Q41930574-F465023C-5E64-4C98-A200-176800DB2DDC Q47105045-8AE1FA5B-4016-48EE-B41B-524761A85193 Q47142488-D8BF72ED-720B-4739-9D3D-8C2F133ECC29 Q47557330-83457F9F-01ED-4FD1-A2DD-A29A830047D4 Q52632456-BD9E6AFD-7F29-4F31-A0FF-A8344E598798

P2860

Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study

http://www.wikidata.org/entity/Q58235659

description

article

@en

im Mai 2014 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в травні 2014

@uk

name

Treatment cessation of entecav ...... multicentre prospective study

@en

Treatment cessation of entecav ...... multicentre prospective study

@nl

type

label

Treatment cessation of entecav ...... multicentre prospective study

@en

Treatment cessation of entecav ...... multicentre prospective study

@nl

prefLabel

Treatment cessation of entecav ...... multicentre prospective study

@en

Treatment cessation of entecav ...... multicentre prospective study

@nl

P1433

Q58235659-C161AB18-439D-4485-A3C9-5669A00F4327

P1476

Q58235659-FBEA067A-44B6-4D2A-A98B-22364D0FF5E4

P2093

Q58235659-067A0582-3E0A-4A14-ACA5-A379B87E2300

Q58235659-32EFFF3B-0D4C-45E0-BDDF-683AA1955625

Q58235659-55E9F1AF-5E66-4185-A7D5-C7E507BFED2F

Q58235659-A4291EB7-9FBC-462F-855F-07ED38E2F18F

Q58235659-D1DA977B-C2E1-41A8-9E63-17CBF3807460

Q58235659-DB5E05C8-5D3B-49BC-A673-A554FEC90184

P2860

Q58235659-0019B805-4C36-4931-97B8-6D4FCBA3C539

Q58235659-00C4BD98-0A41-42EB-94E6-C629A4FEE77C

Q58235659-05D8C19B-2CB3-4AEE-B416-B42AA2ACCB3C

Q58235659-06D8E510-0530-4BFC-A913-B037E4F8C94E

Q58235659-07E87B4F-9787-4179-88FB-B27027CE7B00

Q58235659-0E89A314-36CB-4A6F-9A7F-5B534CBBA86F

Q58235659-11C01A92-2F28-42DF-B55E-241014309C24

Q58235659-15B7EE78-CB63-4DA7-A802-C4E98773732C

Q58235659-16EC6A83-460D-44D3-A159-9FF03CDD183B

Q58235659-17CD981B-93D0-474C-A5F1-866998459C8D

P304

Q58235659-A63CB9C0-7B57-4F7E-B521-BD2E4D8ACB2D

P31

Q58235659-28381470-B13B-4DD0-9F3A-BBE6519A5036

P356

Q58235659-B0D5D164-6666-43AC-B890-EE64BB285DBA

P407

Q58235659-29E2B394-43E6-4372-B5A9-CE4EE15B7982

P433

Q58235659-AC94E358-011F-4B6D-9D15-98027B1BF8E3

P478

Q58235659-9C8CC958-F2BF-49EA-8BBB-E1BFA5C6A18D

P50

Q58235659-17737A8B-429E-4EB7-BFE7-36E0750A7073

Q58235659-FBF66127-9FC0-46DE-A14A-90997839C781

P577

Q58235659-832637AB-9297-4AEB-A503-E40E1CF5F3FA

P698

Q58235659-3DF5B2F4-B4B5-4241-8A9B-A50CBF0198DC

P921

Q58235659-2C20A51E-A041-45BE-8F88-F50BDAA8DB82

P356

GUTJNL-2014-307237

P1433

P1476

Treatment cessation of entecav ...... multicentre prospective study

@en

P2093

Aric Josun Hui

http://www.w3.org/2001/XMLSchema#string

Grace Lai-Hung Wong

http://www.w3.org/2001/XMLSchema#string

Henry Lik-Yuen Chan

http://www.w3.org/2001/XMLSchema#string

Kevin Sze-Hang Liu

http://www.w3.org/2001/XMLSchema#string

Man-Fung Yuen

http://www.w3.org/2001/XMLSchema#string

Vincent Wai-Sun Wong

http://www.w3.org/2001/XMLSchema#string

P2860

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Chronic hepatitis B: update 2009

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Viral hepatitis B.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.

Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.

Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.

P304

667-672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUTJNL-2014-307237

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24833635

http://www.w3.org/2001/XMLSchema#string

P921